One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease.

MLA

Mankerious, Nader, et al. “One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease.” The American Journal of Cardiology, vol. 225, Aug. 2024, pp. 25–34. EBSCOhost, https://doi.org/10.1016/j.amjcard.2024.06.003.

APA

Mankerious, N., Toelg, R., Vogel, B., Sartori, S., Angiolillo, D. J., Vranckx, P., Feng, Y., de la Torre Hernandez, J. M., Krucoff, M. W., Bhatt, D. L., Spirito, A., Cao, D., Chehab, B. M., Kunadian, V., Maksoud, A., Picon, H., Sardella, G., Thiele, H., Varenne, O., … Mehran, R. (2024). One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease. The American Journal of Cardiology, 225, 25–34. https://doi.org/10.1016/j.amjcard.2024.06.003

Chicago

Mankerious, Nader, Ralph Toelg, Birgit Vogel, Samantha Sartori, Dominick J Angiolillo, Pascal Vranckx, Yihan Feng, et al. 2024. “One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease.” The American Journal of Cardiology 225 (August): 25–34. doi:10.1016/j.amjcard.2024.06.003.